Incidence of brain metastases in early stage HER2 3+ breast cancer patients; Is there a role for brain CT in asymptomatic patients?

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 249-253

  Tomasevic, Zorica I ^a   Rakocevic, Z ^a   Tomasevic, Z M ^a   Milovanovic, Z ^a   Inic, M ^a   Kolarevic, D ^a   Lukic, V ^a   Kovac, Z ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Adjuvant trastuzumab; Brain metastases; Early breast cancer; HER2 overexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RELAPSE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RISK ASSESSMENT; SERBIA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84863617002     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lassman A, DeAngelis L. Brain metastases. Neurol Clin 2003; 21: 1-23. (Pubitemid 36169343)
2. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977. (Pubitemid 36676250)
3. Shmuel E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40: 379-382. (Pubitemid 38121275)
4. Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK. Increased rate of brain metastases with trastuzumab therapy does not associate with impaired survival. Clin Breast Cancer 2003; 4: 114-119. (Pubitemid 36939417)
5. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-643. (Pubitemid 39141617)
6. Lin NU, Winer EP. Brain Metastases: The HER2 Paradigm. Clin Cancer Res 2007; 13: 1648-1655. (Pubitemid 46952930)
7. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14: 1072-1077. (Pubitemid 36950171)
8. Lin NU, Bellon J, Winer E. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617. (Pubitemid 41103668)
9. Weitzen R, Zach L, Kaufman B et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002; 20: 31b (abstr 1936).
10. Viani G, Afonso SI, Stefano EJ, DeFendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: Meta analysis of published randomized trials. BMC Cancer 2007; 7: 1-11.
11. Bria E, Cupponoe F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109: 231-239. (Pubitemid 351644860)
12. Tham YL, Sexston K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704. (Pubitemid 44232661)
13. Carey L, Ewend MG, Metzger R et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 2004; 88: 273-280. (Pubitemid 40137306)
14. Gabos Z, Sinba R, Hanson J et al. Prognostic significance of human epidermal growth factor receptor for the development of brain metastasis in newly diagnosed breast cancer. J Clin Oncol 2006; 24: 5658-5663.
15. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944. (Pubitemid 43778983)
16. Chang E, Lo S. Management of central nervous system metastases from breast cancer. Oncologist 2003; 8: 398-410. (Pubitemid 37238868)
17. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu Status. Breast Cancer Res 2006; 8: 36: 1-8.
18. Niwinska A, Tacikowska M, Pienkowski T. Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol 2007; 46: 1027-1029. (Pubitemid 47537186)
19. Niwinska A, Tacikowska M, Murawska M. Effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 2010; 77: 1134-1139.
20. Demicheli R, Miceli R, Moliterni A et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005; 16: 1449-1457. (Pubitemid 41222417)